Brief: Jade Biosciences Announces First Participant Dosed In Phase 2 Juniper Clinical Trial Of Jade101 In Iga Nephropathy
26/05/2026 12:10
May 26 (Reuters) - Jade Biosciences Inc JBIO.O: JADE BIOSCIENCES ANNOUNCES FIRST PARTICIPANT DOSED IN PHASE 2 JUNIPER CLINICAL TRIAL OF JADE101 IN IGA NEPHROPATHY JADE BIOSCIENCES INC - INTERIM DATA FROM JUNIPER PHASE 2 TRIAL EXPECTED IN 2027 Source text: ID:nGNXbL3qg0 Further company coverage: JBIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jade Biosciences
See all newsBrief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million